VivoSeq
Infectious Disease

Mycobacterium Avium Complex

1

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Mycobacterium Avium Complex is an early-stage landscape with 1 program across 3 companies. The most active players are Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Spero Therapeutics, Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

95/100

Attrition Rate

4/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 2S

Spero Therapeutics

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

Azithromycin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

23

clinical trials

Completed20 · 87%
Terminated1 · 4%
Active, not recruiting1 · 4%
Recruiting1 · 4%

Clinical Trials

Trial Activity

23 trials

CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections
Recruiting·—·Phase 3·NCT03236987·424 enrolled
Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC)
Active, not recruiting·OOregon Health and Science University·Phase 2·NCT02968212·102 enrolled
The Safety and Effectiveness of Clarithromycin Plus Zidovudine or Dideoxyinosine in the Treatment of Mycobacterium Avium Complex (MAC) Infections in Children With AIDS
Completed·AAbbott·Phase 1·NCT00000971·24 enrolled
Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND Study
Completed·PPharmacia·N/A·NCT00002080
A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients
Completed·Pfizer logoPfizer·Phase 3·NCT00002122·720 enrolled
Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex
Completed·IInsmed Incorporated·Phase 3·NCT04677569·425 enrolled
A Randomized, Double-Blinded, Placebo-Controlled, Phase II Inhaled Interferon Gamma-1b and Antimycobacterials to Treat Pulmonary Mycobacterium Avium Complex Infections
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00021567·20 enrolled
The Safety and Effectiveness of Clarithromycin and Rifabutin Used Alone or in Combination to Prevent Mycobacterium Avium Complex (MAC) or Disseminated MAC Disease in HIV-Infected Patients
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00001030·1,100 enrolled
Effectiveness of Rifabutin in the Treatment of Mycobacterium Avium Complex
Completed·TThe University of Texas Health Science Center at Tyler·Phase 3·NCT03164291·170 enrolled
Evaluation of Treatment for Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001039·24 enrolled
Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial
Completed·PPharmacia·N/A·NCT00002267·750 enrolled
The Safety and Effectiveness of Clarithromycin in the Prevention of Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients
Completed·AAbbott·N/A·NCT00002336
Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex
Completed·IInsmed Incorporated·Phase 3·NCT04677543·99 enrolled
A Study of Rifabutin, Used Alone or With Ethambutol in the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in Patients With AIDS
Completed·PPharmacia·Phase 4·NCT00002343·200 enrolled
A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001058·246 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)